Skip to content

CLO Rapid Test Panel

by Hangzhou Alltest Biotech.Co., Ltd.

Ref DCL-114

CLO Rapid Test Panel (DCL-114) is an in vitro diagnostic device (EU IVDD general IVD) made by Hangzhou Alltest Biotech.Co., Ltd., registered in EUDAMED on 3 Aug 2026 (Basic UDI-DI B-DCL-114L8), active as of 7 Nov 2026.

Active European Union

CE IVDD

Valid until

No date given

EUDAMED holds no validity date

FDA recalls

Not applicable

No FDA record for this device

Documents

None, self-declared

Class I: no certifier involved

Trust

Unverified

Source EUDAMED, synced 7 Nov 2026.

Regulatory status

as of registry sync 7 Nov 2026

RegionAuthorizationNumberDateStatus
European UnionCE/IVDD NumberB-DCL-114L8 Basic UDI-DI Date3 Aug 2026RegisteredStatusActive

Official records

Certificates

0 certificates · EUDAMED

No certifier certificate is listed. Devices of this class are self-declared by the manufacturer.

Coverage

1 jurisdiction

SwedenFinlandLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaAustriaHungaryRomaniaSloveniaBulgariaPortugalSpainItalyCroatiaGreeceMaltaCyprus
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

European Union — CE/IVDD Active

Specification

EUDAMED

Trade name
CLO Rapid Test Panel
Clonazepam (CLO) Rapid Test Panel
Model / reference
DCL-114
Primary DI / UDI-DI
D-DCL-114L8, 06936983100717
Basic UDI-DI
B-DCL-114L8, B-06936983100717
EMDN code
W0102090104, W0102160599
Device class
Class IVD General
EU registration type
Legacy device (under a directive)
EU market of registration
Austria
Ireland

Manufacturer details

EUDAMED SRN
CN-MF-000010710
Authorised representative
MedNet EC-REP GmbH DE-AR-000000002

Similar devices in this category

Other devices filed under BENZODIAZEPINES.

Other devices from Hangzhou Alltest Biotech.Co., Ltd.

See all devices from Hangzhou Alltest Biotech.Co., Ltd. →

Properties

  • Contains animal tissues or cells
  • Reagent NoEUDAMEDYesEUDAMED
  • IVD kit
  • Professional testing
Other properties (9, all answered No)